Literature DB >> 6697063

Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.

D J Back, F Sutcliffe, J F Tjia.   

Abstract

The effects of various drugs on the pharmacokinetics of tolbutamide have been examined in the rat. Phenobarbitone pretreatment caused a significant decrease in half life and area under the curve (AUC) and a significant increase in clearance and volume of distribution (Vd). Acute administration of primaquine significantly increased half life and AUC and decreased clearance. In contrast, the related animoquinolone chloroquine, was without effect. Acute administration of cimetidine produced similar changes to primaquine but of lesser magnitude. Formation of the major metabolite hydroxytolbutamide, was markedly enhanced by phenobarbitone and reduced by primaquine and cimetidine. We conclude that due to its single pathway of metabolism, tolbutamide is a good substrate to use when examining pharmacokinetic interactions involving hepatic enzyme induction and inhibition.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6697063      PMCID: PMC1986862          DOI: 10.1111/j.1476-5381.1984.tb10109.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  The fate of antipyrine in man.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-01       Impact factor: 4.030

2.  Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes.

Authors:  T D Rogerson; C F Wilkinson; K Hetarski
Journal:  Biochem Pharmacol       Date:  1977-06-01       Impact factor: 5.858

3.  The effect of spironolactone on antipyrine metabolism in man.

Authors:  D H Huffman; D W Shoeman; P Pentikäinen; D L Azarnoff
Journal:  Pharmacology       Date:  1973       Impact factor: 2.547

4.  Imidazole derivatives--a new class of microsomal enzyme inhibitors.

Authors:  C F Wilkinson; K Hetnarski; T O Yellin
Journal:  Biochem Pharmacol       Date:  1972-12-01       Impact factor: 5.858

5.  Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo.

Authors:  C F Wilkinson; K Hetnarski; G P Cantwell; F J Di Carlo
Journal:  Biochem Pharmacol       Date:  1974-09-01       Impact factor: 5.858

6.  Norphenazone, a new metabolite of phenazone in human urine.

Authors:  J D Baty; D A Evans
Journal:  J Pharm Pharmacol       Date:  1973-01       Impact factor: 3.765

7.  Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

Authors:  S M Pond; D J Birkett; D N Wade
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

8.  The metabolic fate of tolbutamide in man and in the rat.

Authors:  R C Thomas; G J Ikeda
Journal:  J Med Chem       Date:  1966-07       Impact factor: 7.446

Review 9.  Drug interactions with oral sulphonylurea hypoglycaemic drugs.

Authors:  J M Hansen; L K Christensen
Journal:  Drugs       Date:  1977-01       Impact factor: 9.546

10.  Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxy tolbutamide in plasma.

Authors:  R L Nation; G W Peng; W L Chiou
Journal:  J Chromatogr       Date:  1978-07-01
View more
  9 in total

1.  Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes.

Authors:  E S Guns; P L Bullock; M L Reimer; R Dixon; M Bally; L D Mayer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

Review 2.  Drug interactions with irbesartan.

Authors:  M R Marino; N N Vachharajani
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Evaluation of hepatic dysfunction in endotoxin pretreated rats using tolbutamide as a marker.

Authors:  J S Kaka; K al-Khamis; M O Tanira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

4.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors:  H S Purba; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

5.  Effect of chlormethiazole on hepatic monooxygenases activity in vivo.

Authors:  H Mönig; D J Back; H T Heidemann; E E Ohnhaus; B Brockmann; H M Schulte
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

6.  Lack of inhibition of tolbutamide hydroxylation by cimetidine in man.

Authors:  C Stockley; J Keal; P Rolan; F Bochner; A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship.

Authors:  D J Back; J F Tjia
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

8.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

9.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.